Core Viewpoint - The company, 麦澜德 (688273.SH), is engaged in the research, development, production, and sales of medical devices related to pelvic floor and obstetric rehabilitation, with a focus on various rehabilitation products and information technology solutions [1] Group 1: Company Overview - 麦澜德 specializes in medical devices for pelvic floor and obstetric rehabilitation, reproductive rehabilitation, anti-aging, sports rehabilitation, consumables, and information technology products [1] - The company's revenue from sports rehabilitation products is currently small and has not significantly impacted overall performance [1]

证券代码：688273 证券简称：麦澜德 公告编号：2025-028 南京麦澜德医疗科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司主要从事盆底及妇产康复领域相关医疗器械产品的研发、生产、销售， 主要产品涵盖盆底及妇产康复、生殖康复和抗衰、运动康复及耗材和信息化产品。 目前运动康复产品收入占比较小，暂未对公司业绩产生重大影响。 公司股价短期波动幅度较大，特别提醒广大投资者，注意投资风险、理性 决策、审慎投资。 一、股票交易异常波动的具体情况 公司股票交易连续三个交易日内（2025 年 8 月 8 日、8 月 11 日、8 月 12 日） 收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证 券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波 动情形。 二、公司关注并核实的相关情况 根据上海证券交易所相关规定，公司对相关问题进行了必要核实。现将相关 情况说明如下： 1、经公司自查，公司目前生产经营情况正常，主营业务未发生重大 ...

Core Viewpoint - The company, 麦澜德, has announced unusual fluctuations in its stock trading, indicating potential market interest or concern regarding its performance in the medical device sector focused on pelvic and gynecological rehabilitation [1] Company Overview - 麦澜德 primarily engages in the research, development, production, and sales of medical devices related to pelvic and gynecological rehabilitation [1] - The company's main product offerings include pelvic and gynecological rehabilitation, reproductive rehabilitation, anti-aging products, sports rehabilitation, consumables, and information technology products [1] Financial Impact - Currently, the revenue contribution from sports rehabilitation products is relatively small and has not significantly impacted the company's overall performance [1]

Core Viewpoint - The company announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of 30% over three consecutive trading days (August 8, August 11, and August 12, 2025) [1] Company Overview - The company specializes in the research, development, production, and sales of medical devices related to pelvic floor and obstetric rehabilitation [1] - Its main product offerings include pelvic floor and obstetric rehabilitation, reproductive rehabilitation, anti-aging, sports rehabilitation, consumables, and information technology products [1] Financial Impact - Currently, the revenue contribution from sports rehabilitation products is relatively small and has not significantly impacted the company's overall performance [1]

Core Insights - A total of 48 stocks on the Shanghai and Shenzhen exchanges have experienced net inflows of main funds for five consecutive days or more, indicating strong investor interest [1] Group 1: Stocks with Significant Net Inflows - Hengshang Energy has seen net inflows for 11 consecutive days, ranking first among the stocks [1] - Agricultural Bank of China ranks second with net inflows for 10 consecutive days, totaling 1.917 billion yuan [1] - BoRui Pharmaceutical follows with net inflows for 8 days, amounting to 868 million yuan [1] Group 2: Performance Metrics - Agricultural Bank of China has the highest total net inflow amount, with a cumulative net inflow of 1.917 billion yuan over 10 days, and a price increase of 11.56% [1] - BoRui Pharmaceutical has a net inflow of 868 million yuan over 8 days, with a price increase of 16.13% [1] - Xinjiang Communications Construction has the highest net inflow ratio at 24.39%, with a price increase of 38.33% over 6 days [1] Group 3: Additional Notable Stocks - Huicheng Environmental Protection and Xinke Materials both recorded net inflows of 606 million yuan over 7 days, with price increases of 14.40% and 18.70% respectively [1] - Fuling Electric Power has a net inflow of 477 million yuan over 9 days, with a significant price increase of 31.03% [1] - Other notable stocks include Huaguang Huaneng and Wanchen Group, with net inflows of 327 million yuan and 315 million yuan respectively, and price increases of 55.15% and 12.61% [1]

Market Overview - As of August 12, the Shanghai Composite Index closed at 3665.92 points, up 18.37 points, with a gain of 0.50% [1] - The Shenzhen Component Index closed at 11351.63 points, up 60.21 points, with a gain of 0.53% [1] - The ChiNext Index closed at 2409.40 points, up 29.58 points, with a gain of 1.24% [1] High Turnover Stocks - A total of 123 A-shares had a turnover rate exceeding 20% on August 12 [1] - Notable stocks with high turnover rates include: - C Guangjian Technology (301632) with a turnover rate of 84.59% and a price increase of 418.45% [1] - Beiwai Technology (002148) with a turnover rate of 60.81% and a price increase of 9.99% [1] - Shuangyi Technology (300690) with a turnover rate of 52.00% and a price increase of 7.60% [1] - C Tianfulong (603406) with a turnover rate of 50.03% and a price decrease of 7.03% [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - Furi Electronics (600203) with a turnover rate of 48.75% and a price increase of 10.03% [1] - Yutian Guanjia (301173) with a turnover rate of 47.38% and a price increase of 12.11% [1] - Weier Gao (301251) with a turnover rate of 46.11% and a price increase of 3.29% [1] - Hengbao Co., Ltd. (002104) with a turnover rate of 44.10% and a price increase of 10.00% [1] Summary of Turnover Rates - The data indicates a strong interest in certain stocks, with several experiencing significant price movements alongside high turnover rates, suggesting potential trading opportunities in the market [1]

Market Overview - The medical device sector rose by 1.16% on August 12, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3665.92, up 0.5%, while the Shenzhen Component Index closed at 11351.63, up 0.53% [1] Top Gainers in Medical Device Sector - Mai Lande (688273) closed at 52.83, up 18.06%, with a trading volume of 150,500 shares and a transaction value of 771 million [1] - Sanxin Medical (300453) closed at 10.75, up 14.24%, with a trading volume of 810,000 shares [1] - Xiangyu Medical (688626) closed at 64.40, up 11.02%, with a trading volume of 102,800 shares [1] - Maipu Medical (301033) closed at 88.80, up 10.38%, with a trading volume of 24,000 shares [1] - Ruimaite (301367) closed at 97.77, up 6.63%, with a trading volume of 33,200 shares [1] Decliners in Medical Device Sector - Kehua Bio (002022) closed at 7.58, down 3.44%, with a trading volume of 417,400 shares [2] - Yirui Bio (300942) closed at 12.91, down 2.93%, with a trading volume of 104,400 shares [2] - Rendu Bio (688193) closed at 51.64, down 2.68%, with a trading volume of 8,204 shares [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 730 million from institutional investors, while retail investors saw a net inflow of 112 million [2] - The top stocks with significant net inflows from retail investors include Yirui Medical and Mai Lande, while major outflows were observed in stocks like Aiyu Technology and Meihua Medical [3]

资金面上，麦澜德上一交易日主力资金净流入3440.43万元，近5日净流入8401.95万元。 融资融券数据显示，该股最新（8月11日）两融余额为1.33亿元，其中，融资余额为1.33亿元，较上一个 交易日减少182.19万元，降幅为1.35%；近10日两融余额合计增加4798.93万元，增幅为56.62%，其间融 资余额增长56.62%。（数据宝） （文章来源：证券时报网） 8月12日盘中科创板股麦澜德涨停，截至10:15，股价报53.70元，成交4.00亿元，换手率21.78%，振幅 18.28%。 科创板个股中，截至发稿上涨的共有129只，涨幅在5%以上的共有13只，涨幅较高的有麦澜德、赛诺医 疗、翔宇医疗等，分别上涨20.00%、13.70%、12.39%，下跌的有452只，跌幅较大的有科兴制药、佳驰 科技、悦康药业，分别下跌6.64%、6.51%、6.21%。 ...

Core Viewpoint - The brain-computer interface (BCI) sector in the A-share market has seen significant gains, driven by recent government policies that elevate BCI from a research field to a national industry strategy [1][2]. Group 1: Market Performance - On August 12, stocks in the BCI sector rose sharply, with Mailland increasing by over 18%, Xiangyu Medical by 12%, and Qisheng Technology by 10% [1]. - Other notable stocks in the sector, such as Innovation Medical, Chengyitong, and Beiyikang, also experienced gains [1]. Group 2: Policy Developments - A joint announcement from seven government departments, including the National Health Commission and the Drug Administration, has been made to promote the innovation and development of the BCI industry, marking a significant policy shift [2]. - Multiple policies have been implemented this year to accelerate the clinical application of BCI technology, including the establishment of pricing guidelines for BCI services by the National Medical Insurance Administration [3]. Group 3: Company Strategies - Chengyitong has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, integrating existing rehabilitation devices with BCI for product upgrades and exploring applications in education, elderly care, and health [4]. - Sanbo Brain Science is actively monitoring BCI technology trends and is focusing on invasive and semi-invasive applications, while also planning to establish a brain science innovation fund for industry investment and collaboration [6].

脑机接口概念股持续走高，麦澜德20%涨停，翔宇医疗涨超14%，麒盛科技、创新医疗涨停。 ...